Kyowa Kirin Co ((KYKOF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Kyowa Kirin Co. is conducting a Phase 2 clinical study titled ‘A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema.’ The study aims to evaluate the efficacy and safety of KHK4951 eye drops in treating Diabetic Macular Edema (DME), a significant cause of vision impairment in diabetic patients.
The study tests KHK4951, a vascular endothelial growth factor receptor inhibitor, administered as eye drops. It is being compared with Aflibercept, a known treatment, to assess its effectiveness in reducing DME symptoms.
This interventional study is randomized and uses a parallel-group design with quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocation. The primary purpose is to evaluate treatment efficacy.
The study began on January 9, 2024, with an estimated primary completion date yet to be disclosed. The latest update was submitted on July 28, 2025, indicating ongoing recruitment and progress.
The study’s outcome could significantly impact Kyowa Kirin’s market position, potentially boosting investor confidence if results are favorable. With competition in the DME treatment market, positive results could enhance the company’s competitive edge.
The study is ongoing, with further details available on the ClinicalTrials portal.